Division of Boston Scientific Corp.
Latest From Ekos Corp.
Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings.
UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the United Kingdom company’s interventional medicines business.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Site Specific
- Radiopharmaceuticals, Contrast Agents
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
Robert Hubert, Pres. & CEO
Matt Stupfel, VP, Fin. & Admin.
- Contact Info
Phone: (425) 415-3100
11911 N. Creek Pkwy. S.
Bothell, WA 98011
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.